Bulletin
Investor Alert

Cerecor Inc.

NAS: CERC

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Dec 13, 2019, 5:09 p.m.

/zigman2/quotes/201368871/composite

$

4.41

Change

0.00 0.00%

Volume

Volume 151

Quotes are delayed by 20 min

/zigman2/quotes/201368871/composite

Previous close

$ 4.40

$ 4.41

Change

+0.01 +0.23%

Day low

Day high

$4.26

$4.79

Open

52 week low

52 week high

$2.71

$7.65

Open

Company Description

Cerecor, Inc. is a clinical stage biopharmaceutical company focuses in medical development. It involves in the discovery, manufacture and commercialization of prescription for neurological and psychiatric disorders. It products include CERC-301, CERC-501, CERC-611, and CERC-406. The company was foun...

Cerecor, Inc. is a clinical stage biopharmaceutical company focuses in medical development. It involves in the discovery, manufacture and commercialization of prescription for neurological and psychiatric disorders. It products include CERC-301, CERC-501, CERC-611, and CERC-406. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher and Solomon H. Snyder on January 31, 2011 and is headquartered in Baltimore, MD.

Valuation

P/E Current

-3.68

P/E Ratio (with extraordinary items)

-7.98

Price to Sales Ratio

6.13

Price to Book Ratio

6.30

Enterprise Value to EBITDA

-12.92

Enterprise Value to Sales

8.85

Total Debt to Enterprise Value

0.13

Efficiency

Revenue/Employee

286,356.00

Income Per Employee

-651,722.00

Receivables Turnover

2.28

Total Asset Turnover

0.32

Liquidity

Current Ratio

0.84

Quick Ratio

0.79

Cash Ratio

0.41

Profitability

Gross Margin

34.46

Operating Margin

-101.33

Pretax Margin

-218.73

Net Margin

-227.59

Return on Assets

-73.52

Return on Equity

-171.06

Return on Total Capital

-57.90

Return on Invested Capital

-132.21

Capital Structure

Total Debt to Total Equity

73.56

Total Debt to Total Capital

42.38

Total Debt to Total Assets

21.86

Long-Term Debt to Equity

68.54

Long-Term Debt to Total Capital

39.49

Officers and Executives

Name Age Officer Since Title
Dr. Simon C. Pedder 58 2018 Executive Chairman
Mr. Joseph M. Miller 45 2018 Secretary, Chief Financial & Accounting Officer
Dr. Perry Calias - 2018 Chief Scientific Officer
Dr. Bernadine Heather Fraser 50 2012 VP-Clinical Operations & Project Management
Mr. Peter S. Greenleaf 47 2017 Director

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
12/10/2019 Pericles Calias
Chief Scientific Officer
2,913   Acquisition at $2.85 per share. 8,302
12/10/2019 Joseph M. Miller
Chief Financial Officer
2,598   Acquisition at $2.85 per share. 7,404
12/10/2019 James A. Harrell
Chief Commercial Officer
3,064   Acquisition at $2.85 per share. 8,732
09/04/2019 Armistice Capital LLC
Director
1,200,000   Acquisition at $3.13 per share. 3,756,000
08/30/2019 Armistice Capital LLC
Director
24,591   Acquisition at $3.23 per share. 79,428
08/29/2019 Armistice Capital LLC
Director
17,173   Acquisition at $3.21 per share. 55,125
08/27/2019 Simon C. Pedder
Executive Chairman of the Bd; Director
6,734   Acquisition at $2.98 per share. 20,067
08/23/2019 Matthew V. Phillips
Chief Commercial Officer
512,500   Award at $1.07 per share. 548,375
08/19/2019 Armistice Capital LLC
Director
0   Acquisition at $0 per share. 0
08/19/2019 Armistice Capital LLC
Director
1,825   Acquisition at $3.63 per share. 6,624
08/19/2019 Armistice Capital LLC
Director
0   Acquisition at $0 per share. 0
08/19/2019 Armistice Capital LLC
Director
473   Acquisition at $3.5 per share. 1,655
08/16/2019 Armistice Capital LLC
Director
0   Acquisition at $0 per share. 0
08/16/2019 Armistice Capital LLC
Director
9,886   Acquisition at $3.43 per share. 33,908
08/14/2019 Armistice Capital LLC
Director
56,842   Acquisition at $3.37 per share. 191,557
08/13/2019 Armistice Capital LLC
Director
29,188   Acquisition at $3.3 per share. 96,320
/news/latest/company/us/cerc

MarketWatch News on CERC

  1. Starboard Value Urges Zayo Group to Sell Itself

    12:10 a.m. March 16, 2019

    - Barron's Online

  2. There’s Value in Damaged Papa John’s Pizza

    7:00 p.m. Oct. 5, 2018

    - Barron's Online

  3. Cerecor Inc. shares drop 37% after midstage trial failure

    8:14 a.m. Dec. 5, 2016

    - Emma Court

  4. Cerecor's stock extends slide, plunges 37% premarket after failed drug trial

    8:09 a.m. Dec. 5, 2016

    - Tomi Kilgore

  5. Cerecor says mid-stage trial of treatment for nicotine withdrawal missed its target

    8:05 a.m. Dec. 5, 2016

    - Ciara Linnane

  6. Cerecor's stock tumbles 14% premarket after drug trial fails to meet primary endpoint

    8:05 a.m. Dec. 5, 2016

    - Tomi Kilgore

  7. Cerecor's stock on track to open at all-time low

    8:06 a.m. Dec. 5, 2016

    - Tomi Kilgore

/news/nonmarketwatch/company/us/cerc

Other News on CERC

  1. Cerecor to acquire Aevi Genomic Medicine

    11:56 a.m. Dec. 5, 2019

    - Seeking Alpha

  2. 10-Q: CERECOR INC.

    4:16 p.m. Nov. 14, 2019

    - Edgar Online - (EDG = 10Q, 10K)

  3. Aytu Bio acquires prescription product portfolio for $17M

    6:32 a.m. Oct. 14, 2019

    - Seeking Alpha

  4. Daily Insider Ratings Round Up 9/6/19

    4:08 p.m. Sept. 9, 2019

    - Seeking Alpha

  5. Cerecor's CERC-802 Fast Track'd for rare metabolic disorder

    6:27 a.m. Aug. 21, 2019

    - Seeking Alpha

  6. Cerecor (CERC) Investor Presentation - Slideshow

    1:43 p.m. Aug. 9, 2019

    - Seeking Alpha

  7. 10-Q: CERECOR INC.

    3:36 p.m. Aug. 8, 2019

    - Edgar Online - (EDG = 10Q, 10K)

  8. FDA OKs Cerecor’s IND for CERC-802

    7:17 a.m. July 29, 2019

    - Seeking Alpha

  9. Daily Insider Ratings Round-Up 5/31/19

    12:54 p.m. June 4, 2019

    - Seeking Alpha

  10. 10-Q: CERECOR INC.

    10:29 a.m. May 10, 2019

    - Edgar Online - (EDG = 10Q, 10K)

  11. Cerecor reports positive Phase I data for CERC-801

    6:05 a.m. April 29, 2019

    - Seeking Alpha

  12. Cerecor changes leadership team

    6:14 a.m. April 11, 2019

    - Seeking Alpha

  13. Daily Insider Ratings Round Up 3/27/19

    7:02 p.m. March 28, 2019

    - Seeking Alpha

  14. Cerecor (CERC) Investor Presentation - Slideshow

    1:34 p.m. March 21, 2019

    - Seeking Alpha

  15. 10-K: CERECOR INC.

    3:34 p.m. March 18, 2019

    - Edgar Online - (EDG = 10Q, 10K)

  16. Loading more headlines...

At a Glance

Cerecor, Inc.

540 Gaither Road

Suite 400

Rockville, Maryland 20850

Phone

1 4105228707

Industry

Pharmaceuticals

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2019

Revenue

$18.33M

Net Income

$-41.71M

Employees

64.00

/news/pressrelease/company/us/cerc

Press Releases on CERC

  1. Cerecor to Acquire Aevi Genomic Medicine

    8:46 a.m. Dec. 5, 2019

    - GlobeNewswire

  2. Cerecor to Acquire Aevi Genomic Medicine

    8:45 a.m. Dec. 5, 2019

    - PR Newswire - PRF

  3. Cerecor to Acquire Aevi Genomic Medicine

    8:45 a.m. Dec. 5, 2019

    - GlobeNewswire

  4. Cerecor Reports Third Quarter 2019 Results

    6:30 a.m. Nov. 14, 2019

    - GlobeNewswire

  5. Cerecor Announces Clinical Updates on CERC-301 and CERC-802

    6:30 a.m. Nov. 11, 2019

    - GlobeNewswire

  6. Cerecor Closes Deal to Sell Pediatric Portfolio

    6:30 a.m. Nov. 4, 2019

    - GlobeNewswire

  7. Cerecor To Sell Pediatric Portfolio to AYTU BioScience

    5:30 a.m. Oct. 14, 2019

    - GlobeNewswire

  8. Cerecor To Sell Pediatric Portfolio to AYTU BioScience

    5:30 a.m. Oct. 14, 2019

    - GlobeNewswire

  9. Cerecor Reports Second Quarter 2019 Results

    3:06 p.m. Aug. 8, 2019

    - GlobeNewswire

  10. Loading more headlines...
Link to MarketWatch's Slice.